Your browser is no longer supported. Please, upgrade your browser.
Settings
ACIU AC Immune SA daily Stock Chart
ACIU [NASD]
AC Immune SA
Index- P/E- EPS (ttm)-0.53 Insider Own51.80% Shs Outstand65.09M Perf Week11.54%
Market Cap283.14M Forward P/E46.77 EPS next Y0.09 Insider Trans0.00% Shs Float40.83M Perf Month-57.56%
Income-32.00M PEG- EPS next Q0.35 Inst Own32.30% Short Float4.24% Perf Quarter-57.31%
Sales22.10M P/S12.81 EPS this Y-226.60% Inst Trans6.27% Short Ratio3.19 Perf Half Y-49.71%
Book/sh2.95 P/B1.47 EPS next Y142.90% ROA-22.40% Target Price10.28 Perf Year-60.09%
Cash/sh3.05 P/C1.43 EPS next 5Y- ROE-25.20% 52W Range3.25 - 17.40 Perf YTD-53.97%
Dividend- P/FCF- EPS past 5Y- ROI-19.20% 52W High-75.00% Beta-
Dividend %- Quick Ratio19.20 Sales past 5Y- Gross Margin- 52W Low33.85% ATR0.59
Employees86 Current Ratio19.20 Sales Q/Q109.10% Oper. Margin- RSI (14)34.87 Volatility8.27% 8.60%
OptionableNo Debt/Eq0.00 EPS Q/Q-35.50% Profit Margin- Rel Volume1.24 Prev Close4.63
ShortableYes LT Debt/Eq0.00 EarningsMar 19 BMO Payout- Avg Volume543.89K Price4.35
Recom1.80 SMA20-18.26% SMA50-48.07% SMA200-53.70% Volume673,570 Change-6.05%
Feb-01-19Downgrade UBS Buy → Neutral
Jan-04-19Initiated UBS Buy
Apr-05-18Initiated H.C. Wainwright Buy $18
Mar-23-18Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Outperform
Oct-18-16Initiated Jefferies Buy $25
Oct-18-16Initiated Credit Suisse Outperform $18
Feb-21-19 08:55AM  Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings? Zacks +9.98%
Feb-20-19 08:54AM  Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings? Zacks
07:35AM  What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings? Zacks
07:00AM  AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimers Disease GlobeNewswire
Feb-07-19 07:00AM  AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development GlobeNewswire
Feb-06-19 09:10AM  What Makes AC Immune (ACIU) a New Buy Stock Zacks
Feb-01-19 08:37AM  AC Immune Enters Oversold Territory Zacks
Jan-30-19 04:47PM  Roche Halts Two Late-Stage Studies on Alzheimer's Candidate Zacks -65.98%
04:42PM  Roche Scraps Alzheimer's Test But Investors Punished This Stock Investor's Business Daily
11:41AM  Roche, AC Immune drop Alzheimer drug trials after setback Reuters
10:16AM  Why AC Immune SA Is Imploding Motley Fool
09:49AM  Genentech kills big drug study in early Alzheimer's patients American City Business Journals
01:36AM  Roche drops Alzheimer drug trials after setback Reuters
01:00AM  AC Immune Reports Discontinuation of Phase III CREAD 1 and 2 Studies of Crenezumab in Alzheimers Disease GlobeNewswire
Jan-25-19 10:30AM  Top Ranked Momentum Stocks to Buy for January 25th Zacks +5.44%
Jan-23-19 10:01AM  Top Ranked Momentum Stocks to Buy for January 23rd Zacks -5.36%
Jan-22-19 06:42AM  Top Ranked Momentum Stocks to Buy for January 22nd Zacks
Jan-17-19 06:56AM  Moving Average Crossover Alert: AC Immune Zacks
Jan-16-19 09:01AM  Stemline Therapeutics (STML) in Focus: Stock Moves 9.5% Higher Zacks
Jan-07-19 03:51PM  Biogen Inks Two Deals to Make Drugs for Neurological Diseases Zacks
Jan-03-19 04:00AM  AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer GlobeNewswire -7.73%
Dec-19-18 07:16AM  WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership PR Newswire -7.92%
06:31AM  AC Immune and WuXi Biologics to Establish an Exclusive Strategic Partnership GlobeNewswire
Dec-13-18 09:00AM  Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug Zacks +5.41%
Dec-12-18 07:51AM  Lilly partners with AC Immune for Alzheimer's treatment Reuters
06:51AM  Lilly partners with AC Immune for Alzheimer's treatment Reuters
06:31AM  AC Immune and Lilly Announce License and Collaboration Agreement GlobeNewswire
06:10AM  Lilly partners with AC Immune for Alzheimer's treatment Reuters
06:00AM  Lilly and AC Immune Announce License and Collaboration Agreement PR Newswire
Dec-07-18 04:16PM  In Memoriam: Dr. Andreas Muhs CSO, Scientific Leader and Friend has Passed Away GlobeNewswire
Dec-06-18 09:42AM  What You Must Know About AC Immune SAs (NASDAQ:ACIU) Beta Value Simply Wall St.
Nov-30-18 05:37AM  AC Immune (ACIU) Shares March Higher, Can It Continue? Zacks
Nov-15-18 04:01AM  AC Immune Awarded Third Follow-up Grant from The Michael J. Fox Foundation for First-in-Human Study of a Positron Emission Tomography (PET) Tracer for Parkinson's Disease GlobeNewswire +9.16%
Nov-13-18 07:30AM  AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01AM  AC Immune Reports Third Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Nov-12-18 04:01AM  AC Immune to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire
Nov-09-18 04:01AM  AC Immune Shares Insights from Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and Other Misfolded Proteins in AD and Neurodegenerative Diseases GlobeNewswire
Nov-05-18 10:30AM  Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline Zacks
Nov-01-18 06:01AM  AC Immune to Present at 2018 Society for Neurosciences Meeting GlobeNewswire +5.31%
05:01AM  AC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and the Involvement of Other Misfolded Proteins in AD and Neurodegenerative Diseases GlobeNewswire
Oct-29-18 06:01AM  AC Immune Partner Life Molecular Imaging Presents New Clinical Study Results for Tau PET-Tracer 18F-PI-2620 GlobeNewswire -5.74%
05:00AM  AC Immune SA: New Data Supporting Crenezumab as Potential Alzheimer's Therapy GlobeNewswire
Oct-25-18 04:00AM  AC Immune Selected to Present Progress on its Tau Morphomer Program in the Late Breaking News Session at CTAD Conference in Barcelona GlobeNewswire -7.79%
Oct-22-18 04:01AM  AC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence GlobeNewswire -5.50%
Oct-17-18 08:35AM  Investor Expectations to Drive Momentum within Matthews International, AC Immune SA, Entercom Communications, Sunrun, Axcelis Technologies, and Advanced Disposal Services Discovering Underlying Factors of Influence GlobeNewswire
Aug-22-18 08:15AM  Recent Analysis Shows STMicroelectronics N.V, Jagged Peak Energy, Inovalon, AC Immune SA, Repligen, and RealNetworks Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-20-18 04:01AM  AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer's Disease and Down Syndrome GlobeNewswire
Aug-08-18 07:30AM  AC Immune (ACIU) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01AM  AC Immune Reports Second Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Jul-31-18 04:06PM  AC Immune Announces Successful Closing of Second Subscription Rights Offering GlobeNewswire
Jul-25-18 05:55PM  New Phase 2 Data Analysis for Crenezumab Presented at Global Alzheimer's Conference Provides Strong Evidence for Engagement of the Principle Abeta Target GlobeNewswire
Jul-23-18 08:31PM  AC Immune Announces Closing of First Subscription Rights Offering and Primary Offering as well as Full Exercise of Option to Purchase Additional Shares GlobeNewswire
Jul-19-18 02:04PM  Here's Why AC Immune SA Rose as Much as 21.6% Today Motley Fool +21.48%
Jul-18-18 07:17PM  AC Immune Announces Price of USD 11.75 for Offerings and Issuance of up to 10 Million Common Shares GlobeNewswire
Jul-17-18 04:09PM  AC Immune Announces Offerings and Issuance of up to 10 Million Common Shares GlobeNewswire
04:01AM  Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited - Updates on AC Immune's Pipeline and Technology Platforms to be presented at AAIC in Chicago GlobeNewswire
Jul-06-18 07:19AM  AC Immune Announces Results of Annual General Meeting GlobeNewswire +38.28%
Jun-08-18 07:55AM  Research Report Identifies AC Immune SA, Vipshop, Infosys, STMicroelectronics N.V., BRF S.A., and National Steel with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
May-02-18 06:50PM  What Does AC Immune SAs (NASDAQ:ACIU) Ownership Structure Look Like? Simply Wall St.
08:43AM  Moving Average Crossover Alert: AC Immune SA (ACIU) Zacks
04:00AM  AC Immune Reports First Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Apr-27-18 04:31PM  AC Immune Announces Results of Extraordinary Shareholders Meeting GlobeNewswire
Apr-20-18 03:54PM  Will AC Immune SAs (NASDAQ:ACIU) Earnings Grow Over The Next Few Years? Simply Wall St.
Apr-05-18 04:01AM  AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's disease GlobeNewswire -11.11%
Apr-03-18 07:20AM  Wired News MediciNova Released Results of Phase-2 Clinical Trial Assessing MN-166 (ibudilast) in Methamphetamine Dependence ACCESSWIRE +12.49%
Mar-27-18 08:30AM  Investor Expectations to Drive Momentum within Ambev S.A, AC Immune SA, Comp En De Mn Cemig ADS, GSV Capital, Novartis AG, and New York Discovering Underlying Factors of Influence GlobeNewswire
Mar-23-18 11:59AM  AC Immune Promising On Alzheimer's, But Light On Short-Term Catalysts, Says Credit Suisse Benzinga -9.12%
Mar-20-18 05:21PM  AC Immune posts 4Q profit Associated Press
05:00AM  AC Immune reports full-year 2017 financial results - successful first year as a public company GlobeNewswire
Mar-15-18 05:00AM  AC Immune prepares for a first in human study of a promising positron emission tomography (PET) tracer for Parkinson's disease GlobeNewswire
Feb-06-18 08:31AM  AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Conference GlobeNewswire
Dec-27-17 08:37AM  AC Immune SA :ACIU-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-18-17 05:25PM  AC Immune SA (NASDAQ:ACIU) And The Healthcare Industry Prospect For 2017 Simply Wall St.
Dec-01-17 02:20PM  AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases GlobeNewswire
Nov-28-17 07:50AM  AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : November 28, 2017 Capital Cube
Nov-24-17 12:25PM  AC Immune SA (ACIU): Financial Strength Analysis Simply Wall St.
Nov-21-17 08:32AM  AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases GlobeNewswire +13.11%
Nov-16-17 12:25PM  AC Immune SA Value Analysis (NASDAQ:ACIU) : November 16, 2017 Capital Cube
Nov-15-17 07:49AM  AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : November 15, 2017 Capital Cube
Nov-13-17 04:35PM  AC Immune reports 3Q loss Associated Press
06:48AM  AC Immune SA Reports Third Quarter 2017 Financial Results and Corporate Update GlobeNewswire
Nov-02-17 06:23AM  AC Immune SA to Receive Milestone Payment for Anti-Tau Antibody Moving into Phase 2 Trial for Alzheimer's Disease GlobeNewswire
Oct-24-17 05:41AM  AC Immune to Present at Two Investor Conferences and Provide Scientific Updates at CTAD Conference GlobeNewswire
Oct-03-17 04:55AM  AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinson's Research GlobeNewswire
Sep-12-17 06:05AM  AC IMMUNE COMPLETES RECRUITMENT FOR LOW-DOSE COHORT IN WORLD'S FIRST CLINICAL TRIAL FOR ANTI-ABETA VACCINE TARGETING ALZHEIMER'S DISEASE-LIKE CHARACTERISTICS IN INDIVIDUALS WITH DOWN SYNDROME GlobeNewswire
Sep-05-17 09:44AM  AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : September 5, 2017 Capital Cube
Aug-29-17 09:32PM  AC Immune SA Value Analysis (NASDAQ:ACIU) : August 30, 2017 Capital Cube
Aug-24-17 07:00AM  Corporate News Blog - Moleculin Biotech to Meet European Medicines Agency; Discussion on Clinical Trial Authorization for the Treatment of Acute Myeloid Leukemia ACCESSWIRE
Aug-23-17 08:51AM  AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : August 23, 2017 Capital Cube
Aug-22-17 10:37AM  AC IMMUNE DISCOVERS NEXT-GENERATION ANTIBODIES FOCUSED ON NEURODEGENERATIVE DISEASES GlobeNewswire +5.77%
Aug-09-17 06:45AM  AC IMMUNE REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS GlobeNewswire
Jul-10-17 07:56AM  AC IMMUNE PROVIDES SEVEN UPDATES ON ITS PIPELINE AND TECHNOLOGY AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE GlobeNewswire
Jun-28-17 07:40AM  AC IMMUNE ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING GlobeNewswire
Jun-26-17 08:38AM  AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : June 26, 2017 Capital Cube
Jun-09-17 09:21AM  AC Immune SA :ACIU-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017 Capital Cube
May-22-17 04:37AM  AC IMMUNE AND ESSEX BIO-TECHNOLOGY ANNOUNCE RESEARCH COLLABORATION FOR NEURODEGENERATIVE DISEASES AND NEUROINFLAMMATION GlobeNewswire
May-11-17 07:08AM  AC Immune reports 1Q loss Associated Press
06:14AM  AC IMMUNE SA REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS GlobeNewswire
Apr-03-17 06:03AM  Piramal Imaging and AC Immune present first clinical data for tau PET-imaging tracer at International Alzheimer's Conference GlobeNewswire
Mar-23-17 12:23PM  AC Immune SA :ACIU-US: Earnings Analysis: Q4, 2016 By the Numbers : March 23, 2017 Capital Cube
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase III clinical studies for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase I/IIa clinical study for AD; and ACI-35, an anti-Tau vaccine candidate against phosphorylated pathological tau and is in Phase Ib clinical testing in patients with mild to moderate AD, as well as RO7105705, an anti-Tau monoclonal antibody candidate, which is in Phase II clinical study for AD patients. In addition, the company has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. It has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Piramal Imaging; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics, as well as Nestle Institute of Health Sciences. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.